Agreement expected to upgrade customer payments.
Mural Health, provider of participant management platform Mural Link, announced it will join ProofPilot’s digital protocol automation platform as a partner to improve participant payments.
“At ProofPilot, we have always seen a higher degree of patient compliance when payments can be automated and closely tied to a wide variety of tasks. Most are unaware of the number of hidden activities needed for a patient to execute during a study outside of the explicit tasks,” said Chris Venezia, CEO of ProofPilot. “Through the strategic partnership of our digital protocol automation platform, along with Mural Health’s participant payment capabilities, we will make it easier for our sites and patients to successfully conduct and participate in research by increasing the efficiency to complete tasks, procedures, and now, patient payments.”
Reference: Mural Health and ProofPilot Partner to Streamline Payments and Provide More Patient Choice. Berwyn, PA and New York, NY, USA, MARCH 14, 2023.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.